2012 Annual Meeting | Multiple Sclerosis Overview I: Basic Science

Date Monday 04/23/12

Time 09:00 AM - 01:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type AM Half-Day Course

Director(s) Bruce A. Cree, MD, PhD, MAS, FAAN

Topic(s) Imaging, Neurogenetics

Learning Objectives Participants should be familiar with current concepts of multiple sclerosis pathogenesis with respect to the complex interplay of environmental and genetic contributions to disease susceptibility, how recent advances in neuro-ophthalmology are being applied to clinical trials and medical practice and understand the essential immunological mechanisms, effects, and safety profiles of current disease-modifying treatments.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Practice-based Learning and Improvement

Recommended Audience Trainee, General Neurologist

Teaching Styles Didactic, Interactive

Program Evaluations

Event Timeline
09:00 AM - 09:45 AM		Multiple Sclerosis Epidemiology Brenda L. Banwell, MD, FAAN
09:45 AM - 09:50 AM		Questions and Answers Brenda L. Banwell, MD, FAAN
09:50 AM - 10:35 AM		Multiple Sclerosis Genetics Bruce A. Cree, MD, PhD, MAS, FAAN
10:35 AM - 10:40 AM		Questions and Answers Bruce A. Cree, MD, PhD, MAS, FAAN
10:40 AM - 11:05 AM		Break
11:05 AM - 11:45 AM		Neuro-ophthalmology of Multiple Sclerosis Laura J. Balcer, MD, MSCE, FAAN
11:45 AM - 11:50 AM		Questions and Answers Laura J. Balcer, MD, MSCE, FAAN
11:50 AM - 12:45 PM		Mechanisms of Action of Current Disease-modifying Therapies Scott S. Zamvil, MD, PhD, FAAN
12:45 PM - 12:50 PM		Questions and Answers Scott S. Zamvil, MD, PhD, FAAN
12:50 PM - 01:00 PM		Discussion

Faculty Disclosures
Scott S. Zamvil, MD, PhD, FAAN	Dr. Zamvil has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Zamvil has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Horizon. The institution of Dr. Zamvil has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. The institution of Dr. Zamvil has received research support from Sumaira Foundation. Dr. Zamvil has received personal compensation in the range of $5,000-$9,999 for serving as a Advisory Board with Genzyme. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board with Genentech. Dr. Zamvil has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board with Alexion.
Laura J. Balcer, MD, MSCE, FAAN	Dr. Balcer has received personal compensation for serving as an employee of North American Neuro-Ophthalmology Society. An immediate family member of Dr. Balcer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Children's Hospital of Philadelphia.
Brenda L. Banwell, MD, FAAN	Dr. Banwell has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Banwell has received personal compensation in the range of $0-$499 for serving as a Consultant for UCB. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Banwell has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Banwell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Genentech. Dr. Banwell has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Banwell has received research support from National MS Society. The institution of Dr. Banwell has received research support from NIH.
Bruce A. Cree, MD, PhD, MAS, FAAN	The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Autobahn. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avotres. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neuron23. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Pharma. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal/Sandoz. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyverna. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. The institution of Dr. Cree has received research support from Genentech. The institution of Dr. Cree has received research support from Kyverna. Dr. Cree has received publishing royalties from a publication relating to health care.

��ɫ��

��ɫ��